Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
TATT TAT Technologies Ltd
STOR STORE Capital Corp
NGG National Grid PLC
MDXG MiMedx Group Inc
GOGR Go Green Global Technologies Corp
APINX AMG Beutel Goodman International Equity Fund - Class N
SVBL Silver Bull Resources Inc
MYMD MyMD Pharmaceuticals Inc

Health Care : Pharmaceuticals | Large Cap Blend
Company profile

Johnson & Johnson is a diversified healthcare products company. The Company is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer Health, Pharmaceutical and MedTech. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension. The MedTech segment includes a range of products used in the interventional solutions, orthopaedics, surgery, and vision fields. Its geographic area includes the United States, Europe, Western Hemisphere (excluding the United States), and Africa, Asia and Pacific.


Last Trade
0.09 (0.06%)
B/A Size

Market Hours

Closing Price
Day's Change
-6.23 (-3.70%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

US Nuclear Corp. Announces Third Quarter 2022 Results

8:30 am ET November 30, 2022 (Globe Newswire) Print
US Nuclear Corp. Announces Third Quarter 2022 ResultsGlobeNewswireNovember 30, 2022

LOS ANGELES, CA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - US Nuclear Corp. (OTCQB: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the third quarter ended September 30, 2022.

For the nine months ended September 30, 2022:

  • Sales were $1,539,517 up slightly from $1,454,153 for the same period in 2021
  • Gross margins were still strong at 45.6% versus 47.0% for the same period in 2021
  • Net loss of $1,671,743 is a major improvement from $2,390,256 for the same period in 2021

For the three months ended September 30, 2022:

  • Sales were $617,434 compared to $683,771 for the same period in 2021
  • Selling, general, and administrative expense were $695,381 compared to $747,290 for the same period in 2021, the decrease of $51,909 or 7.5% due to the company cutting back on expenses
  • Net loss of $655,822 compared to $444,383 for the same period in 2021

Robert Goldstein, CEO of US Nuclear Corp., commented:

"We had a strong third quarter and have executed well this year despite facing challenging conditions such as supply chain shortages and rising cost of parts and skilled labor. We continue to reduce our operating costs and have also recently increased the prices we charge for all our products and services. As nuclear energy becomes more popular and as fears of chemical-nuclear war or terrorism mount, we have seen an increase in demand for our equipment that continues to grow. We are especially excited about our DroneRAD platform and the advanced chemical detection capability it now has (can even detect explosives, war gases, and drugs such as fentanyl), as well as the introduction of industry's first and only portable PFAS monitors to quickly measure the toxic 'forever chemicals'."

Three Months EndedNine Months Ended
September 30, September 30,
Cost of sales405,471357,426837,523770,780
Gross profit211,963326,345701,994683,373
Operating expenses
Selling, general and administrative expenses695,381747,2902,103,6372,228,295
Total operating expenses695,381747,2902,103,6372,228,295
Loss from operations(483,419)(420,945)(1,401,644)(1,544,922)
Other income (expense)
Interest expense(31,710)(3,016)(37,650)(9,872)
Equity loss in investment-(20,422)-(835,462)
Expense for debt issuance----
Amortization of debt discount(140,693)-(232,449)-
Total other income (expense)(172,403)(23,438)(270,099)(845,334)
Loss before provision for income taxes(655,822)(444,383)(1,671,743)(2,390,256)
Provision for income taxes----
Net loss$(655,822)$(444,383)$(1,671,743)$(2,390,256)
Deemed dividend for downround provision in warrants(9,652)(52,861)
Net loss attributed to common stockholders$(655,822)$(444,383)$(1,681,395)$(2,443,117)
Weighted average shares outstanding - basic and diluted29,504,43327,914,30228,923,13227,072,892
Loss per shares - basic and diluted$(0.02)$(0.02)$(0.06)$(0.09)

Safe Harbor Act

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at, or the company's website at


US Nuclear Corp. (OTC-QB: UCLE)

Robert I. Goldstein, President, CEO, and Chairman

Richard Landry, Chief Financial Officer

(818) 883 7043


Primary Logo

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.